U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07750041) titled 'A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer' on Aug. 02.
Brief Summary: This study constitutes an open-label, multi-cohort, multi-center Phase Ib/II clinical study, developed to assess the safety, tolerability, and therapeutic efficacy of SYS6090 injection when administered in combination with bevacizumab, or in triple combination with bevacizumab and chemotherapy, among patients diagnosed with advanced colorectal cancer.
Study Start Date: Aug. 30
Study Type: INTERVENTIONAL
Condition:
Unresectable Advanced or Metastatic Colorectal Cancer
Intervention:
DRUG: SYS6090 (Fixed Dose Level A) + bev...